New 'Smart Bomb' drug trial offers hope for Tough-to-Treat bile duct cancer
NCT ID NCT06178588
Summary
This study is testing a drug called sacituzumab govitecan in people with advanced bile duct cancer (cholangiocarcinoma) that has come back or spread after at least one prior treatment. The drug is designed to target cancer cells specifically, delivering a toxic agent directly to them. The main goal is to see if the drug shrinks tumors and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Kansas Cancer Center
Kansas City, Kansas, 66160, United States
Conditions
Explore the condition pages connected to this study.